KalVista Pharmaceuticals Inc has terminated a mid-stage trial of its prophylactic drug candidate for hereditary angioedema (HAE) following safety issues but is holding out hope for a more advanced on-demand program for the rare disease.
The US firm said it had terminated the Phase II KOMPLETE trial of KVD824 for the prevention of HAE attacks because multiple treated participants experienced liver enzyme elevations, although importantly
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?